.jpg "Halozyme (NASDAQ: HALO)")
Yesterday, a Director at Halozyme (HALO), Kenneth Kelley, bought shares of HALO for $748.2K.
This recent transaction increases Kenneth Kelley’s holding in the company by 27.72% to a total of $3.86 million.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.06 and a one-year low of $12.71. The Company has a Price to Book ratio of 22.1981.
Five different firms, including BMO Capital and Canaccord Genuity, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.
